Moody National Bank Trust Division Buys Shares of 17,728 Repligen Corporation $RGEN

Moody National Bank Trust Division purchased a new position in Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, Holdings Channel reports. The fund purchased 17,728 shares of the biotechnology company’s stock, valued at approximately $2,419,000.

Several other institutional investors have also added to or reduced their stakes in RGEN. Price T Rowe Associates Inc. MD grew its position in shares of Repligen by 31.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after acquiring an additional 1,091,683 shares during the period. United Capital Financial Advisors LLC purchased a new stake in shares of Repligen in the 3rd quarter worth $368,387,000. Opti Capital Management LP purchased a new stake in shares of Repligen in the 4th quarter worth $2,399,209,000. Maverick Capital Ltd. bought a new position in Repligen in the 1st quarter worth $178,946,000. Finally, Invesco Ltd. raised its holdings in Repligen by 43.9% in the 4th quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock worth $205,880,000 after purchasing an additional 383,399 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.60% of the stock is currently owned by company insiders.

Repligen Stock Up 1.8%

RGEN opened at $149.78 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $175.77. The firm’s fifty day moving average is $135.99 and its 200 day moving average is $131.12. The stock has a market cap of $8.45 billion, a price-to-earnings ratio of 205.18, a price-to-earnings-growth ratio of 2.68 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same quarter in the prior year, the firm posted $0.26 EPS. Repligen’s quarterly revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, sell-side analysts forecast that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on RGEN shares. Rothschild & Co Redburn set a $160.00 price target on Repligen and gave the company a “buy” rating in a report on Friday, April 17th. Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research note on Tuesday, July 7th. Zacks Research raised Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Royal Bank Of Canada initiated coverage on Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective on the stock. Finally, Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, July 14th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $166.43.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.